Literature DB >> 19336789

Mortality and tardive dyskinesia: long-term study using the US National Death Index.

Charles E Dean1, Paul D Thuras.   

Abstract

BACKGROUND: Whether the development of tardive dyskinesia leads to an increase in mortality is still unclear. AIMS: To explore the relationship between tardive dyskinesia and mortality over a 10-year period, using the National Death Index.
METHOD: Death certificates were obtained from the National Death Index on 1621 people repeatedly assessed for tardive dyskinesia by trained raters. Variables with the potential for influencing survival time were also investigated.
RESULTS: Tardive dyskinesia was significantly associated with an increase in mortality (P<0.001), but this association became non-significant when drug course and age were entered in the regression analysis. Those who had taken only conventional antipsychotics were twice as likely to die compared with those taking atypical agents (P<0.02). For those aged 53-65 years, conventional agents were associated with a sevenfold increase in mortality.
CONCLUSIONS: Older individuals with tardive dyskinesia treated with conventional antipsychotics appear to have a shortened survival time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336789     DOI: 10.1192/bjp.bp.108.049395

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  8 in total

1.  Movement Disorders and Mortality in Severely Mentally Ill Patients: The Curacao Extrapyramidal Syndromes Study XIV.

Authors:  Anne E Willems; Charlotte L Mentzel; Pieter Roberto Bakker; Jim Van Os; Diederik E Tenback; Petra Gelan; Erna Daantjes; Glenn E Matroos; Hans W Hoek; Peter N Van Harten
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

2.  The paradox of premature mortality in schizophrenia: new research questions.

Authors:  Hiram Joseph Wildgust; Richard Hodgson; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

Review 3.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

Review 4.  The genetics of drug-related movement disorders, an umbrella review of meta-analyses.

Authors:  Nadine C van der Burg; Asmar F Y Al Hadithy; Peter N van Harten; Jim van Os; P Roberto Bakker
Journal:  Mol Psychiatry       Date:  2020-02-04       Impact factor: 15.992

Review 5.  Mortality in schizophrenia: a measurable clinical endpoint.

Authors:  Chris J Bushe; Mark Taylor; Jari Haukka
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

6.  Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder.

Authors:  P Roberto Bakker; Izaäk W de Groot; Jim van Os; Peter N van Harten
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

7.  The Role of Cannabis within an Emerging Perspective on Schizophrenia.

Authors:  Jegason P Diviant; Jacob M Vigil; Sarah S Stith
Journal:  Medicines (Basel)       Date:  2018-08-08

8.  Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases.

Authors:  Wei Zhang; Cunlong Zhang; Feng Liu; Yu Mao; Wei Xu; Tingting Fan; Qinsheng Sun; Shengnan He; Yuzong Chen; Wei Guo; Ying Tan; Yuyang Jiang
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.